Cure8 news brief
Perianal fistulas are a significant complication of Crohn’s disease that can be hard to treat. A phase 3 trial reported that guselkumab improved combined fistula remission versus placebo, which could represent a new treatment option if confirmed and approved.
Adults with perianal fistulizing Crohn’s disease, clinicians who treat IBD, and researchers interested in biologic therapies targeting IL‑23.
This report summarizes Week 24 results presented at DDW 2026 from a randomized, double‑blind, placebo‑controlled phase 3 trial showing efficacy of an IL‑23 inhibitor for perianal fistulizing Crohn’s disease. The primary endpoint combined clinical closure and MRI confirmation of no significant collections.
The authors describe guselkumab as the first randomized trial to show efficacy of an IL‑23p19 antagonist in this specific manifestation. If you have perianal Crohn’s disease: these are trial results, not prescribing guidance.
Additional details (longer follow‑up, regulatory decisions, full published data) are needed before this would change clinical practice. For safety and individual treatment decisions, talk with your gastroenterologist.
Results are Week 24 data presented at a conference; full peer‑reviewed publication and longer‑term outcomes, safety details, and regulatory review are needed. The trial population had prior inadequate response to multiple therapies, which is relevant when considering generalizability.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Cure8 could only read part of this source from rttnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Guselkumab, and IL-23 inhibitor.
This reports phase 2b trial results showing a fixed-dose combination of two biologics (anti‑TNF + anti‑IL‑23) improved outcomes in people with refractory IBD compared with one biologic alone.
This reports Phase 2b results for a new investigational biologic (JNJ-4804) that targets both IL-23 and TNF and showed higher clinical and endoscopic responses in patients with refractory UC and CD — a group with few...
